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S342 Poster Session IICare Alliance. Clinical information was obtained from the institu-
tional database.Multiple linear regressionwas used to analyze the pa-
tient and transplant characteristics that are associatedwith total costs.
Results:Median age was 50 years (range 21 to 69 years), and 62%
patients were male. Seventy eight percent transplants were for
acute leukemia/MDS. Reasons for second transplant were graft
failure (25%), relapse of original disease (65%) and other causes
e.g. secondary MDS/aplasia (10%). 73% of relapsed patients
were in remission at the time of the second transplant. Non-mye-
loablative conditioning was more common in the second allografts
(75%) than in first allografts (30%) and a higher proportion of sec-
ond allografts were from unrelated donors (76% vs. 43%). In the
first 100 days, relapse occurred in 25% patients and 64% experi-
enced $ grade II acute GVHD. Survival was 78% at 100 days
and 49% at one year after transplant. Regimen related toxicity ac-
counted for 75% of deaths within the first 100 days. The median
total cost in 2010 dollars was $137,600 ($4,500 - $434,200) for
the first 100 days, with approximately $135,600 (0 - $432,200)
for inpatient and $4,100 (0 - $17,200) for outpatient costs. The me-
dian length of hospital stay was 22 days (range 0 to 77 days). Mye-
loablative conditioning, unrelated donors and pulmonary
complications post-transplant were significant predictors of higher
costs for the second transplants.
Table 1. Predictors of costs for second allogeneic transplant
Variable Cost multiplier 95%CI p valuePre-transplant factors
Age
<50 1
>50 0.89 0.53-1.47 0.64Disease
Acute leukemia/MDS 1
Lymphoma 0.65 0.28-1.48 0.31
Others 3.18 0.90-11.2 0.08Diseases status
Remission 1
Relapse 0.76 0.38-1.49 0.43Graft source
PBSC 1
BM 0.97 0.26-3.66 0.97
cord blood 0.83 0.35-1.94 0.67Conditioning
myeloablative 1
Non-myeloablative 0.45 0.23-0.86 0.02Year of transplant
Per year 0.88 0.73-1.06 0.18Reason for transplantTable 1. Guidelines for routine serum GM testing followingRelapse 1allogeneic HSCTGraft rejection 1.18 0.64-2.19 0.6
Others 1.48 0.45-4.95 0.52Patients undergoing myeloablative conditioning regimenDonor type
 Day 30-60 post transplant: weekly galactomannanRelated 1
 Day 60+ post transplant: weekly galactomannan for patients on$ 1 mg/kgUnrelated 2.39 1.34-4.25 0.006
steroids or ANC < 1000CMV serostatusNonmyeloablative conditioning regimennegative 1
 Day 30+: weekly galactomannan for patients on $ 1 mg/kg steroids orpositive 0.83 0.50-1.37 0.48
ANC < 1000Post-transplant complications
within 100 days
Death (n 5 12) 0.9 0.37-2.20 0.82
Relapse (n 5 14) 1.15 0.64-2.07 0.65
GVHD (II-IV) (n 5 35) 1.59 0.96-2.64 0.08
VOD (n 5 10)* 1.16 0.52-2.58 0.72
Pulmonary (n 5 5) 2.08 1.05-4.12 0.04
Renal (n 5 9) 1.58 0.59-4.18 0.37
Infection (n 5 29) 1.62 0.96-2.73 0.08*Veno-occlusive disease
Conclusion: Short-term costs of second transplants appear compa-
rable to those of first transplants especially since a majority of them
are non-myeloablative/reduced intensity regimens. Additional work
is neededwith larger numbers of patients to confirm these results and
identify additional characteristics that would predict the group with
the best clinical and economic outcomes.373
CLINICAL UTILITY OF THE GALACTOMANNAN ASSAY AS A SCREENING
TOOL FOR INVASIVE ASPERGILLOSIS FOLLOWING ALLOGENEIC HEMA-
TOPOIETIC STEM CELL TRANSPLANT
Keating, T.M., Casper, C., Fredricks, D. Fred Hutchinson Cancer Re-
search Center, Seattle, WA
Background: Invasive aspergillosis (IA) can result in significant
morbidity for immunosuppressed patients, particularly after alloge-
neic hematopoietic stem cell transplant (HSCT). The serum galac-
tomannan (GM) assay has been utilized as a tool to facilitate early
detection of IA, however its clinical usefulness for screening has
not been well studied. Routine screening was performed at our cen-
ter for patients considered to be at highest risk of IA (Table 1) and
a review was conducted to determine whether this improved case
finding.
Methods: Clinical data, including demographics, transplant history
and GM testing was reviewed for all adult allogeneic transplant re-
cipients seen at our Center in 2008. Probable and proven cases of
IA were identified by chart review of patients with positive culture,
pathology, PCR or GM from serum, bronchoalveolar lavage, or
other clinical site and classified according to EORTC criteria for di-
agnosis of IA. AGMcut-off of$ 0.5 in a single sample defined a pos-
itive result.
Results: A total of 1,939 serum GM assays were performed in 2008
in 239 patients for a mean of 8.1 tests per patient. Six percent (n 5
117) of tests were positive in 49 patients. Of those, 20 patients
(41%) met the diagnosis of IA. The sensitivity of the GM assay in
this screening settingwas 31%with a specificity of 95%and a positive
predictive value of 25%.
There were 32 cases of IA identified in 2008. Thirteen (41%) of
the identified cases clearly met criteria for GM screening at our cen-
ter and only seven of these cases had a positive serum GM prior to
diagnosis. A positive serum GM led to diagnosis of IA in three pa-
tients. Other cases were identified during evaluation of respiratory
tract infection symptoms (n5 13), fever (n5 9), routine radiological
imaging (n5 5), or follow up of previously identified pulmonary dis-
ease (n 5 2).
Conclusions: The GM assay demonstrated poor sensitivity as
a screening tool in a population of adult patients following allogeneic
HSCT. Despite recommendations for routine screening in patients
at highest risk for IA, the galactomannan contributed to case finding
in only three of 32 identified cases. Most cases did not meet recom-
mendations for routine screening and did not have a positive GM
prior to diagnosis. GM has low value as a screening tool in HSCT
when employed using the guidelines described here.374
THE HEMATOPOIETIC CELL TRANSPLANTATION-SPECIFIC COMORBID-
ITY INDEX (HCT-CI) AND SURVIVAL FOLLOWING EXTRACORPOREAL
PHOTOPHERESIS, PENTOSTATIN, AND REDUCED DOSE TOTAL BODY IR-
RADIATION CONDITIONING
Hashmi, S., Oliva, J.L., Liesveld, J.L., Phillips, G.L., Nichols, D.,
Milner, L., Becker, M. University of Rochester, Rochester, NY
Background: The HCT-CI has been reported to be an informative
tool to predict survival after myeloablative and fludarabine-based re-
duced intensity conditioning SCT. Recipient age, disease type, dis-
ease status, and donor relatedness have also been associated with
survival. The specific aims of this study were to describe SCT recip-
ients who received photopheresis, pentostatin, and 2-6Gy total body
Table 1. Risk factor analysis of transplant outcomes in 72
patients with T-ALL treated with haplo-identical/mismatched
HSCT
Risk factor LFS Relapse NRM
HLA non-identical locus
1-2 n 5 31 52% 24% 17%
3 n 5 41 39% 21% 35%
p 0.15 0.77 0.068
Gender
Male n 5 55 51% 21% 21%
Female n 5 17 16% 27% 53%
p 0.040 0.61 0.08
Diagnostic WBC
Less than 100 n 5 57 48% 23% 23%
100 or more n 5 15 27% 22% 46%
p 0.27 0.99 0.22
CNS involvement
Yes n 5 12 58% 33% 8%
No n 5 60 37% 21% 33%
p 0.44 0.29 0.09
Tumor mass
Yes n 5 38 37% 33% 32%
No n 5 34 52% 10% 24%
p 0.14 0.02 0.64
Time from chemo to CR1
#30d n 5 40 48% 18% 28%
>30d n 5 32 38% 29% 26%
p 0.12 0.19 0.70
Disease status before HSCT
CR1 n 5 56 58% 18% 16%
Non-CR1 n 5 16 12% 37% 50%
p 0.001 0.08 0.04
Disease duration before HSCT
#7 months n 5 38 50% 23% 23%
>7 monts n 5 34 37% 22% 33%
p 0.42 0.96 0.39
Age
< 35 years n 5 59 42% 26% 24%
$35 years n 5 13 47% 8% 43%
p 0.87 0.17 0.12
Median MNCs, x108/kg
#7.5 n 5 36 40% 21% 34%
>7.5 n 5 36 50% 24% 22%
p 0.61 0.58 0.15
Poster Session II S343irradiation (PPTBI) and evaluate these variables as predictors of
post-SCT survival.
Design & Methods: The study employed a retrospective, descrip-
tive design with convenience sampling of patients treated with
PPTBI at the University of Rochester Medical Center 2001-2010;
De-identified data were extracted from the medical records on IRB
approved protocol. All statistical analyses were performed utilizing
SPSS 19.0.
Results: In the final sample size of 103 patients, mean recipient age
was 56.6 (SD9.9; range 20-70). The sample was 34% female and 66%
male. Disease type included ALL (1.9%), AML (33%), CLL
(20.4%), CML (4.9%), HL (4.9%), MDS (8.7%), MM (1.9%),
MPN (6.8%), NHL (16.5%), and PCD (1%). Disease status in-
cluded: 1st response (30.1%), 2nd response (38.8%), refractory
(16.5%), untreated (4.9%), and other (9.7%). Related (43.7%) and
unrelated (56.3%) donors were utilized. HCT-CI scores were cate-
gorized into low (10.7%), intermediate (31.1%), and high (58.3%)
risk. Median survival was 298 days (SD825.4; range10-2881);
38.8% were alive at study endpoint. Bivariate analyses (alpha 5
.05) revealed a significant association between survival and age, dis-
ease type, disease status, and HCT-CI category (all p\.001), but not
donor relatedness. Survival was regressed on the explanatory vari-
ables with stepwise addition of HCT-CI which remained the only
significant predictor of survival in this sample (c2 5 11.35, df 2,
p 5 .003). Subjects in low (HR .31,95% CI:.101,.961, p 5 .042)
and intermediate (HR .41, 95%CI:.214,.775, p 5 .006) groups by
HCT-CI had significantly better survival compared to those in the
high risk group.
Conclusion:Our findings contribute to the validity and reliability of
HCT-CI as a predictor of survival after reduced intensity SCT in all
types of hematologic malignancies. We conclude that the HCT-CI
assessment should routinely be performed to facilitate risk estima-
tion and decision-making with patients who are considering SCT
and further prospective studies are needed to confirm these
findings.
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A NOVEL PROTOCOL FOR HAPLOIDENTICAL HSCT WITHOUT IN VITRO
T CELL DEPLETION IN THE TREATMENT OF SEVERE ACQUIRED APLASTIC
ANEMIA
Xu, L.-P., Liu, K.-Y., Liu, D.-H., Han, W., Chen, H., Chen, Y.-H.,
Zhang, X.-H., Wang, Y., Wang, F.-R., Wang, J.-Z., Huang, X.-J. Pe-
king University People’s Hospital, Peking Univeristy Institute of Hematol-
ogy, Beijing, China
Mismatched related donor HSCT for severe aplastic anemia
(SAA) presents challenges, mainly associated with graft failure and
GVHD. Non-engraftment and graft rejection after allo-HSCT for
SAA has been strongly associated with higher degrees of histoincom-
patibility and allosensitization to histocompatibility antigens due to
previous blood product transfusions. Earlier reports have suggested
that the greater the HLA disparity, the poorer the overall survival
(OS), less than 20% survival for two or more loci-mismatched recip-
ients. Recently, progress has been made in haploidentical HSCT,
which is now used to perform haploidentical non-T-cell-depleted
HSCT for patients with hematological malignancies, it is not known
whether the similar procedure could be used for patients with SAA.
We report the results of 19 consecutive SAA/VSAA patients who re-
ceived haploidentical-HSCT. All cases failed to previous therapy and
were heavily transfused prior to transplantation. Among these, 9
cases had 3 loci mismatches, 9 cases had 2 loci mismatches, and 1
case had 1 locus mismatch. All patients were treated with a regimen
which consisted of the following: busulfan (6.4mg/kg i.v. in 8 doses);
cyclophosphamide (200mg/kg, i.v. in 4 doses); and ATG (10mg/kg
i.v.,rabbit, of the Sangstat product or 80mg/kg i.v.,porcine,the Bio-
product, Wuhan, in 4 doses).All recipients received CsA, mycophe-
nolate mofetil, and short-term MTX for GVHD prophylaxis. The
source of stem cell grafts was a combination of G-CSF-primed
BM and G-CSF-mobilized peripheral blood stem cells. All patients
achieved 100%donormyeloid engraftment; themedian time formy-
eloid engraftment was 12 days (ranging from 10-29 days) and 18 days
(ranging from 8-180 days) for platelets, with a cumulative platelet en-
graftment incidence of 84.21 6 10.53%. Two patients (10.5%) suf-
fered late graft rejection. The cumulative incidence was 42.1 6
11.3% for grade II-IV acute GVHD (aGVHD) and 21.1 6 9.4%for grade III-IV aGVHD. The cumulative incidence was 56.2 6
12.4% for chronic GVHD (cGVHD) and 12.56 8.3% for extensive
cGVHD.Of 13 surviving patients with amedian 746 d (90-1970) fol-
low-up, OS was 64.66 12.4%. The independent high risk factors to
OS are grade II-IV aGVHD and mononuclear cells (MNC) infused
\8.84x108/kg. These limited data suggest that HLA-mismatched/
haploidentical HSCT for SAA patients without an HLA-identical
sibling donor may be feasible. Properly controlled trials will be
needed to confirm this conclusion.
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HAPLO-IDENTICAL/MISMATCHED HEMATOPOIETIC STEM CELL TRANS-
PLANTATION WITHOUT IN VITRO T-CELL DEPLETION FOR T-CELL
ACUTE LYMPHOCYTIC LEUKEMIA
Wang, Y.1, Liu, D.-H.2, Xu, L.-P.3, Liu, K.-Y.4, Chen, H.5,
Chen, Y.-H.6, Han, W.7, Zhang, X.-H.8, Huang, X.-J.9 1Peking Uni-
versity People’s Hospital, Institute of Hematology; 2Peking University
People’s Hospital, Institute of Hematology; 3Peking University People’s
Hospital, Institute of Hematology; 4Peking University People’s Hospital,
Institute of Hematology; 5Peking University People’s Hospital, Institute
of Hematology; 6Peking University People’s Hospital, Institute of Hematol-
ogy; 7Peking University People’s Hospital, Institute of Hematology; 8Peking
University People’s Hospital, Institute of Hematology; 9Peking University
People’s Hospital, Institute of Hematology
The outcome of T-cell acute lymphoblastic leukemia (T-ALL)
is poorly understood. Allogeneic hematopoietic stem cell
